|
|
Credits: 0.5 CME / 0.6 CNE
|
Expired
|
|
Novel combination regimens have had a profound effect on the treatment of patients with multiple myeloma. In this interactive learning activity, Charles M. Farber, MD, PhD, draws on his clinical experience to discuss current treatment strategies for treating multiple myeloma patients, the clinical benefits of using novel agents in treatment regimens, and the place for novel agents in transplantation protocols.
|
|
|
|
|
Credits: 1.0 CME / 1.0 CNE
|
Expired
|
|
Multiple myeloma remains an incurable disease for the majority of patients. The goal of maintenance therapy is to help patients achieve and maintain a durable remission. In this learning activity, Ashraf Badros, MD, discusses the role of maintenance therapy when treating multiple myeloma and examines recommended treatment strategies for various patient cohorts.
|
|
|
|
|
|
Credits: 1.0 CME / 1.0 CNE
|
Expired
|
|
Multiple myeloma is an incurable hematologic malignancy characterized by a highly variable duration of response and long-term outcomes, with treatment relapse remaining a key issue. In this learning activity, blood oncology expert Sagar Lonial, MD, offers his expertise on individualized treatment strategies for multiple myeloma patients and compares clinical evidence for utilizing novel agent-based regimens in different patient cohorts. This activity also features additional commentary from Charise Gleason, MSN, NP-C, AOCNP.
|
|
|
|
|
|
Credits: 0.5 CME / 0.5 CNE
|
Expired
|
|
Multiple myeloma patients can develop painful bone lesions, and despite their treatment, most lesions fail to heal completely. In this podcast learning activity, Adam D. Cohen, MD, discusses the available diagnostic imaging modalities used in the detection and management of bone disease in multiple myeloma patients, and examines the clinical practice guidelines for the use of bisphosphonates and novel therapeutic agents in treating myeloma bone disease.
|
|
|
|
|
|
Credits: 0.5 CME / 0.5 CNE
|
Expired
|
|
New approaches to multiple myeloma therapy, including the use of novel immunomodulatory agents, have significantly improved patient outcomes. In this learning activity, Sagar Lonial, MD, provides clinical insight on how to effectively manage new treatment approaches for patients with multiple myeloma. He will also address how comorbidities and adverse events affect treatment strategies.
|
|
|
|
|
|
Credits: 1.0 CME / 1.0 CNE
|
Expired
|
|
Combination treatment strategies involving novel agents have helped to transform the treatment of multiple myeloma, culminating in improved outcomes and increased survival for many patients. This learning activity provides a concise review of the novel agents thalidomide, lenalidomide, and bortezomib and their incorporation into frontline treatment regimens supported by Level I evidence from 2009 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.
|
|
|
|
|
|
Credits: 1.25 CME / 1.3 CNE
|
Expired
|
|
Paul G. Richardson, MD, and Mecide M. Gharibo, MD, team up to discuss the importance of targeting therapy and tailoring patient care in the treatment of multiple myeloma (MM) in this 2-part learning activity. A slide presentation from Dr. Richardson precedes a Q&A exchange between Dr. Richardson and Dr. Gharibo, in which both doctors share their views on such topics as the influence of comorbidities on treatment strategies, the nuances of combination treatment regimens, the impact of cytotoxic agents on toxicity, and the need for tailored treatments to achieve optimal outcomes. Additional topics addressed in this CME activity include emerging data on the physiologic role of the bone marrow microenvironment in MM and recent advances in diagnosis, staging, and response assessment.
|
|
|
|
|
|
Credits: 0.75 CME / 0.7 CNE
|
Expired
|
|
The emergent understanding of the bone marrow microenvironment has played an important role in the development of novel agents that have changed the standard of care for patients with multiple myeloma. The addition of proteasome inhibitors and immunomodulatory drugs to the therapeutic armamentarium has led to improved treatment strategies and increased survival rates. In this activity, blood oncology expert Peter M. Voorhees, MD, discusses the biologic effects of current targeted therapies for multiple myeloma and the potential for new agents under development to target disease pathogenesis and further improve patient outcomes.
|
|
|
|
|
|
Credits: 0.5 CME / 0.5 CNE
|
Expired
|
|
How has treatment for multiple myeloma (MM) advanced in the past several years? Although MM remains an incurable malignancy, great therapeutic opportunities exist to enable improved patient survival. Noted medical oncologist Paul G. Richardson addresses questions concerning MM and the developments in clinicians’ understanding of the disease that have led to new treatment options and therapeutic combinations.
|
|
|
|
|
|
Credits: 0.5 CME / 0.5 CNE
|
Expired
|
|
Mecide M. Gharibo, MD, draws on her clinical expertise in medical oncology to discuss issues in multiple myeloma treatment. As part of her discussion, Dr. Gharibo explores how emerging therapies, current standards of care, close patient monitoring, and consideration of comorbidities may be employed to enhance patient outcomes and improve survival.
|
|
|
|
|
|
Credits: 0.75 CME / 0.8 CNE
|
Expired
|
|
The treatment of multiple myeloma is changing dramatically. Stem cell transplants and the approval of two new classes of drugs, immunomodulators and proteasome inhibitors, have led to improved responses and increased survival among patients with multiple myeloma. This monograph provides clinicians with a comprehensive overview of the latest data in this rapidly changing field.
|
|
|
|
|
|
Credits: 0.5 CME / 0.5 CNE
|
Expired
|
|
The emergence of numerous therapies in recent years has led to significant advances in the treatment of multiple myeloma. Dr. Bensinger draws upon his clinical expertise to discuss how these emerging therapies and the current standards of care may be employed to enhance patient outcomes and improve survival.
|
|
|
|
|